Dec 2, 2025 · Litfulo In June 2023, the FDA approved another JAK inhibitor, LITFULO® (ritlecitinib), for the treatment of severe alopecia areata in adults and adolescents ages 12 and …

Apr 24, 2024 · Ritlecitinib is an exciting new treatment; however, it is important to remember that it is for the treatment of severe alopecia areata only and will not work for other hair loss types …

Ritlecitinib and baricitinib are recently approved systemic treatments for severe alopecia areata (AA). Both demonstrated superiority over placebo in hair regrowth measured by the Severity of …

Sustained hair regrowth is achieved with continued ritlecitinib treatment. Some patients achieve clinical responses later; therefore, longer-term treatment is warranted in patients without early …

Safety Results from ALLEGRO No treatment differences between ritlecitinib 50 mg QD and placebo were observed in rates of serious adverse events, discontinuations due to adverse …

LITFULO (ritlecitinib) is a prescription medicine used to treat severe alopecia areata in adults and adolescents 12 years and older.

Feb 14, 2025 · While patients with alopecia areata with extensive scalp hair loss benefitted from 24 months of ritlecitinib treatment, patients with less extensive scalp hair loss had higher …

LITFULO® (ritlecitinib) Clinical Studies 14 CLINICAL STUDIES The efficacy and safety of LITFULO were evaluated in one randomized, double-blind, placebo-controlled trial (Trial AA-I) …

Jan 29, 2025 · Across subgroups, safety was similar. "The majority of ritlecitinib-treated patients with AA who met target clinical response based on scalp, eyebrow, or eyelash regrowth at …

A board-certified dermatologist will know the most about alopecia areata and be able to evaluate treatment effectiveness in hair regrowth personalized to your treatment goals. How long do I …